2022-501910-79-01招募中2 期
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 73
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical trial contact point
Scientific
Fondazione IRCCS Istituto Nazionale Dei Tumori
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, phase Ib/II trial (NICHOL TRIAL)MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864Ovarian cancerCTIS2022-501910-79-01Fondazione IRCCS Istituto Nazionale Dei Tumori73
进行中（未招募）
1 期
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)EUCTR2017-003552-23-BEJanssen-Cilag International NV140
进行中（未招募）
1 期
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)EUCTR2017-003552-23-GBJanssen-Cilag International NV140
进行中（未招募）
1 期
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with JNJ-63723283 in men with metastatic castration-resistant prostate cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 20.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003552-23-ESJanssen-Cilag International NV60
进行中（未招募）
1 期
A study to evaluate the tolerability, safety and anti-tumor effect of Niraparib in combination with different anticancer agents in men with metastatic castration-resistant prostate cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003552-23-ITJANSSEN CILAG INTERNATIONAL NV140